Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;22(9):1260-8.
doi: 10.1111/ene.12629. Epub 2015 Jan 23.

Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability

E Ben-Menachem  1 , D Revesz  1 , B J Simon  2 , S Silberstein  3
Affiliations
Review

Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability

E Ben-Menachem et al. Eur J Neurol. 2015 Sep.

Abstract

Vagus nerve stimulation (VNS) is effective in refractory epilepsy and depression and is being investigated in heart failure, headache, gastric motility disorders and asthma. The first VNS device required surgical implantation of electrodes and a stimulator. Adverse events (AEs) are generally associated with implantation or continuous on-off stimulation. Infection is the most serious implantation-associated AE. Bradycardia and asystole have also been described during implantation, as has vocal cord paresis, which can last up to 6 months and depends on surgical skill and experience. The most frequent stimulation-associated AEs include voice alteration, paresthesia, cough, headache, dyspnea, pharyngitis and pain, which may require a decrease in stimulation strength or intermittent or permanent device deactivation. Newer non-invasive VNS delivery systems do not require surgery and permit patient-administered stimulation on demand. These non-invasive VNS systems improve the safety and tolerability of VNS, making it more accessible and facilitating further investigations across a wider range of uses.

Keywords: depression; epilepsy; headache; implantable; migraine; safety; transcutaneous; vagus nerve stimulation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Vagus nerve innervation. (Reprinted with permission from Massey 9).
Figure 2
Figure 2
Implantable VNS systems: (a) VNS Therapy system and (b) CardioFit. (Reprinted with permission from (a) Cyberonics, Houston, TX, USA, and (b) BioControl Medical, Yehud, Israel).
Figure 3
Figure 3
Non‐implantable VNS systems: (a) NEMOS (tVNS) and (b) gammaCore (nVNS). (Reprinted with permission from (a) Cerbomed, Erlangen, Germany, and (b) electroCore, Basking Ridge, NJ, USA).
See this image and copyright information in PMC

References

    1. Beekwilder JP, Beems T. Overview of the clinical applications of vagus nerve stimulation. J Clin Neurophysiol 2010; 27: 130–138. - PubMed
    1. Ben‐Menachem E, Manon‐Espaillat R, Ristanovic R, et al Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994; 35: 616–626. - PubMed
    1. Ben‐Menachem E. Vagus nerve stimulation, side effects, and long‐term safety. J Clin Neurophysiol 2001; 18: 415–418. - PubMed
    1. Goadsby P, Lipton R, Cady R, Mauskop A, Grosberg B. Non‐invasive vagus nerve stimulation (nVNS) for acute treatment of migraine: an open‐label pilot study [abstract S40.004]. Presented at Annual Meeting of the American Academy of Neurology, 16−23 March 2013, San Diego, CA.
    1. Jurgens TP, Leone M. Pearls and pitfalls: neurostimulation in headache. Cephalalgia 2013; 33: 512–525. - PubMed

MeSH terms